Brokers Issue Forecasts for PLRX FY2025 Earnings

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Pliant Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings per share of ($4.46) for the year. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.65) per share.

Pliant Therapeutics (NASDAQ:PLRX) last issued its earnings results on Thursday, November 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.04.

Separately, HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of Pliant Therapeutics in a research note on Friday, November 8th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $40.50.

Pliant Therapeutics Price Performance

Pliant Therapeutics stock opened at $10.92 on Wednesday. The company has a current ratio of 10.26, a quick ratio of 10.26 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $13.24 and a 200 day moving average price of $13.08. Pliant Therapeutics has a 12-month low of $10.22 and a 12-month high of $18.92. The stock has a market cap of $664.53 million, a P/E ratio of -3.27 and a beta of 1.05.

Insider Activity

In other news, insider Hans Hull sold 15,936 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $178,483.20. Following the completion of the transaction, the insider now owns 211,558 shares of the company’s stock, valued at approximately $2,369,449.60. This trade represents a 7.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Mike Ouimette sold 13,270 shares of Pliant Therapeutics stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $11.20, for a total transaction of $148,624.00. Following the completion of the transaction, the general counsel now owns 80,774 shares of the company’s stock, valued at $904,668.80. This trade represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 91,855 shares of company stock valued at $1,026,628. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Pliant Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. boosted its holdings in Pliant Therapeutics by 18.1% in the second quarter. American Century Companies Inc. now owns 74,113 shares of the company’s stock valued at $797,000 after purchasing an additional 11,351 shares during the period. Dimensional Fund Advisors LP raised its holdings in Pliant Therapeutics by 1.7% in the second quarter. Dimensional Fund Advisors LP now owns 305,322 shares of the company’s stock valued at $3,282,000 after acquiring an additional 5,152 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Pliant Therapeutics by 233.8% in the second quarter. Renaissance Technologies LLC now owns 253,369 shares of the company’s stock worth $2,724,000 after acquiring an additional 177,469 shares during the last quarter. Ensign Peak Advisors Inc grew its holdings in Pliant Therapeutics by 39.1% during the 2nd quarter. Ensign Peak Advisors Inc now owns 35,368 shares of the company’s stock worth $380,000 after acquiring an additional 9,950 shares in the last quarter. Finally, Great Point Partners LLC increased its position in shares of Pliant Therapeutics by 42.4% in the 2nd quarter. Great Point Partners LLC now owns 2,636,864 shares of the company’s stock valued at $28,346,000 after purchasing an additional 785,000 shares during the last quarter. Hedge funds and other institutional investors own 97.30% of the company’s stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.